Pharmaceutical Companies

BYPHAR is designed to simplify raw material selection while helping manufacturers meet increasingly stringent quality and regulatory requirements throughout the development and production process.

The acquisition follows Novartis AG’s decision in 2024 to review the future of its India-listed subsidiary.

The investment will upgrade Resilience’s manufacturing operations in Ohio, where the company has produced Lilly’s Mounjaro and Zepbound since the partners began working together in 2023.

The partnership combines Budenheim’s manufacturing expertise with Brenntag’s biopharma services and distribution network.

Under the agreements, MSD will work with Aspen Pharmacare in South Africa, Quality Chemicals Industries Limited (QCIL) in Uganda and Universal Corporation Limited (UCL) in Kenya.

The initiative comes as scientists intensify efforts to address a major Bundibugyo ebolavirus outbreak, with cases rising rapidly in the Democratic Republic of the Congo (DRC).

Repatha lowers low-density lipoprotein cholesterol (LDL-C), a key risk factor for cardiovascular disease, alongside other measures to manage cardiovascular risk.

RushData aims to address these bottlenecks by bringing antibody expression, binding analysis and early developability profiling into a standardised workflow.

Under the agreement, CORE Biomedicine will evaluate and develop the licensed programmes with the aim of creating targeted treatments for a wider range of cancer patients.

The approval makes Simtriyo the first norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD and gives Otsuka what Jefferies analysts described as its “next major CNS launch.”